Hospital
Sheridan Community Hospital
Sheridan Community Hospital was paid $1.92M by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 37% of everything it billed.
33Billing provider infoSHERIDAN COMMUNITY HOSPITAL
SHERIDAN, MI 48884
SHERIDAN, MI 48884
33aNPI1689618324assigned 06/15/2006
33bProvider typeCritical Access Hospital
28Total paid$1.92M
24GClaims54,766
24DCodes billed64
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Michigan
Rank by total paid#22 of 31
Median peer was paid$6.03M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,044 | $191K | |
| 2019 | 4,226 | $120K | |
| 2020 | 6,031 | $211K | |
| 2021 | 12,016 | $425K | |
| 2022 | 9,650 | $369K | |
| 2023 | 9,422 | $346K | |
| 2024incomplete | 6,377 | $259K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 37% | 9,283 | 8,672 | $713K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 1,927 | 1,804 | $280K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 1,054 | 944 | $224K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 2,519 | 2,444 | $214K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 1,834 | 1,768 | $116K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.5% | 891 | 839 | $106K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 2,176 | 2,116 | $30K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 659 | 631 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.4% | 1,492 | 1,438 | $28K |
| 87428 | 1.3% | 879 | 866 | $24K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 806 | 740 | $22K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 666 | 197 | $17K |
52 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 435 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 4,543 | $17K |
| 80061 | Lipid panel | <1% | 1,694 | $15K |
| 99285 | Emergency room visit (most serious) | <1% | 15 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,224 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,736 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,875 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 951 | $6K |
| 80305 | <1% | 584 | $5K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 509 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 56 | $1K |
| 85027 | <1% | 656 | $1K | |
| 80306 | <1% | 280 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 343 | $840.79 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 574 | $823.34 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 37 | $784.99 |
| 87077 | <1% | 439 | $717.42 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 595 | $646.37 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,672 | $630.81 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 37 | $628.59 |
| 81025 | <1% | 682 | $284.45 | |
| 87070 | <1% | 653 | $266.14 | |
| 81001 | <1% | 1,166 | $261.08 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16 | $252.46 |
| 99001 | <1% | 41 | $244.72 | |
| 82607 | <1% | 31 | $236.85 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 255 | $191.69 |
| 87143 | <1% | 54 | $170.10 | |
| 85610 | <1% | 155 | $141.43 | |
| 81003 | <1% | 297 | $101.51 | |
| 83690 | <1% | 193 | $82.54 | |
| 84439 | <1% | 13 | $78.43 | |
| 87430 | <1% | 221 | $62.05 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32 | $60.21 |
| 83605 | <1% | 171 | $40.32 | |
| 87807 | <1% | 41 | $31.08 | |
| 85007 | <1% | 60 | $27.50 | |
| 81002 | <1% | 100 | $19.67 | |
| 84484 | <1% | 12 | $17.02 | |
| 81000 | <1% | 195 | $16.80 | |
| 85730 | <1% | 39 | $11.34 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,594 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 44 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 63 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 46 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 607 | $0.00 |
| J3490 | Unclassified drugs | 0% | 53 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 38 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 32 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 309 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 100 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPETRICEVIC, LJILJANA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Sheridan Community Hospital | Sheridan, MI | $820K |
| Sheridan Community Hospital | Sheridan, MI | $749K |
| Sheridan Community Hospital | Sheridan, MI | $69K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.